Published: January 14, 2025

InSphero CSO Dr. Madhu Nag Appointed to SLAS Board of Directors

January 14, 2025 – Zurich, Switzerland

InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, is proud to announce that Chief Scientific Officer, Dr. Madhu Nag, has been appointed as a member of the Society for Laboratory Automation and Screening (SLAS) Board of Directors, serving a three-year term starting January 1, 2025. Dr. Nag will also take on the role of Board Secretary.

Dr. Nag brings over two decades of expertise in developing New Approach Methodologies (NAMs) and advancing 3D in vitro technologies. Her distinguished career includes leadership roles at NCATS/NIH, FDA, Day One Biopharmaceuticals, and her current position at InSphero, where she leads a team of experts in 3D cell culture solutions for drug safety and efficacy testing.

A passionate advocate for the integration of biology with technology, Dr. Nag has been an active member of SLAS since 2002. She has contributed as a presenter, workshop organizer, and educator. Her appointment reflects her commitment to innovation and fostering the next generation of leaders in laboratory automation. “I am honored to join the SLAS Board and work alongside brilliant scientists to enable and build on the wonderful work that has already been established,” commented Madhu Nag.

“This appointment is a testament to Madhu’s exceptional contributions to the field of 3D cell culture and her vision for advancing New Approach Methodologies,” said Dr. Jan Lichtenberg, CEO and Co-Founder of InSphero, who served as a Board Member from 2021 to 2023 and was SLAS President in 2023. “This is a proud moment for us at InSphero, and I am personally excited about the continuation of our deep ties with SLAS.”

Dr. Nag will join fellow SLAS board members and industry leaders to shape the future of laboratory automation and life sciences innovation. She will attend the SLAS Annual Meeting in San Diego, January 25-29 2025, along with 3D Cell Culture experts from InSphero.

Other News

News

InSphero Appoints Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer

InSphero has appointed Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer, expanding his leadership role as the company continues to grow and scale. With nearly a decade at InSphero and deep expertise across microfluidics, BioMEMS, 3D in vitro models, and organ-on-chip technologies, Olivier will bring technology and operations into closer alignment. In his new role, he will help advance operational efficiency, digitalization, automation, and technology development across the organization.

Read More »
News

InSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity Assessment 

InSphero has launched the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput solution designed to identify gastrointestinal safety liabilities earlier in drug discovery. Combining patient-derived human intestinal organoids, scalable Gri3D® technology, and automated phenotypic imaging, the platform delivers quantitative, decision-ready insights while enabling more consistent and streamlined GI safety assessment.

Read More »

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource